{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-115048","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.938769+00:00","generated_at":"2026-06-08T14:23:34.845249+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Milestone to host webcast Nov 13 on etripamil Phase 2 AFib-RVR study results","bullets":["Webcast on Monday Nov 13, 2023 at 8:00 a.m. ET to discuss ReVeRA Phase 2 results of etripamil in AFib-RVR.","Key opinion leaders A. John Camm, MD, and Sean Pokorney, MD, will join the webcast.","Results presented as Featured Science at AHA Scientific Sessions 2023.","Dial-in: (877) 870-4263 (domestic) or (412) 317-0790 (international).","Webcast and slides accessible via News & Events section of Milestone's IR website."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-115048","json":"https://secwatch.observer/filing/0001104659-23-115048.json","markdown":"https://secwatch.observer/filing/0001104659-23-115048.md","text":"https://secwatch.observer/filing/0001104659-23-115048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923115048/0001104659-23-115048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923115048/tm2330059d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T14:23:34.845249+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}